Ricerca avanzata

Home > Riviste > Minerva Gastroenterologica e Dietologica > Fascicoli precedenti > Minerva Gastroenterologica e Dietologica 2014 Settembre;60(3) > Minerva Gastroenterologica e Dietologica 2014 Settembre;60(3):165-75

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOMINERVA GASTROENTEROLOGICA E DIETOLOGICA

Rivista di Gastroenterologia, Nutrizione e Dietetica


Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index

 

Minerva Gastroenterologica e Dietologica 2014 Settembre;60(3):165-75

AGGIORNAMENTI NEL TRATTAMENTO DELL’EPATITE VIRALE 

Management of hepatitis C virus and human immunodeficiency virus coinfection

O’neil C. R. 1, Coffin C. S. 1, 2

1 Department of Internal Medicine, Faculty of Medicine, University of Calgary, Calgary, Canada;
2 Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Calgary, Calgary, Canada

With the success of highly active antiretroviral therapy in treating HIV, liver disease has emerged as a major cause of morbidity and mortality amongst HCV and HIV coinfected patients. Until recently, the treatment of HCV in HIV positive patients with interferon based regimens and/or first generation directly acting antiviral agents (DAAs) yielded lower sustained virological response (SVR) rates compared to HCV monoinfected patients and treatment was limited by significant side effects and drug-drug interactions. The introduction of second generation DAAs has led to a remarkable improvement in treatment outcomes of HCV/HIV coinfected patients with >90% achieving a SVR with relatively simple and short treatment courses and with minimal adverse effects. In this article, we provide a comprehensive overview of the epidemiology, diagnosis, approach to screening, and treatment of HIV/HCV coinfected patients. We focus particularly on the use of DAAs in this historically difficult to treat HCV-positive patient population.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina